Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a sirtuin boost make dieting more effective?

NCT ID NCT07802548

Disease control Sponsor: Poznan University of Life Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 03, 2026 · Last updated Sep 04, 2026 · Updated 1 time

Summary

Researchers are testing whether a supplement that activates sirtuins, proteins linked to metabolism, can enhance weight loss in adults with overweight or obesity. In this 24-day trial, participants follow a weight loss diet and receive either the supplement or a placebo. The study measures changes in body weight, body composition, and physical function to see if the supplement adds benefit beyond diet alone.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A dietary supplement containing sirtuin activators (EGCG, resveratrol, quercetin, niacin, curcuminoids) taken alongside a weight loss diet
What this could lead to
If it works, this could point toward a supplement that helps overweight and obese adults lose more weight and improve metabolic health when combined with a diet.
What could go wrong
The trial is small (45 people) and lasts only 24 days, so any effects may be short-lived or not apply to everyone. Supplements can also cause side effects, and the results may not justify long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

45 people

The number who actually took part.

Started

Jan 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI: 25-35 kg/m2 * stable body weight (change less than 10% in the last 3 months) * age: 18-65 years * both sexes Exclusion Criteria: * age \<18 or \>65 years * BMI \<25 or \>35 kg/m2 * body weight change more than 10% in the last 3 months * GLP-1RA treatment * bariatric surgery in the past * hypertension≥160/100 mmHg * unstable heart disease * pregnancy and breastfeeding * insulin treatment or unstable diabetes * Active and unstable liver, kidney, thyroid, gastroenterological diseases * the use of curcuminoids, resveratrol, quercetin, EGCG supplements 3 months prior to study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity & overweight are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity & overweight

Contacts and locations

Locations

  • Poznan University of Life Sciences

    Poznan, Wielkopolska, 60-637, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.